Corindus Vascular Robotics said it’s launching a 20-patient trial of its CorPath robot-assisted surgery device in treating peripheral artery disease.
Corindus Vascular Robotics
Medigus secures $5.6M in funding, reveals positive outcomes from study of its MUSE surgical endostapling device | Medtech funding for the week of September 15, 2014
Medigus raises $5.6M, touts clinical results for acid reflux device
September 12, 2014 by Arezu Sarvestani
Corindus raises $26.6M for vascular robot
Massachusetts-based Corindus Vascular Robotics has big plans for its newly secured $26.6 million, raised in a private placement funding round.
Corindus sold nearly 10.7 million shares at $2.50 apiece through a Securities Purchase Agreement, with Cowen & Co. and Stifel, Nicolaus & Co. acting as placement agents.
Robotics: Philips and Corindus sign deal for surgical robot
Corindus Vascular Robotics granted Philips (NYSE:PHG) distribution rights to sell the newly cleared CorPath 200, a robot-assisted surgical system for performing minimally invasive heart procedures.
The deal, the financial terms of which were not disclosed, allows Philips to distribute the CorPath 200 system in the U.S.
FDA clears Corindus Vascular’s robot assisted remote-controlled PCI system
Natick, Mass.-based medical device company Corindus Vascular Robotics won FDA clearance for the 1st robot-assisted surgical system designed for percutaneous coronary intervention, the CorPath 200.
The CorPath 200 is the "1st and only robotic-assisted procedure to allow for controlled placement of coronary guidewires and stent/balloon catheters from an optimized interventional cockpit," according to the company.
HRS 2012: New imaging may better predict who needs an ICD | MassDevice.com On Call
MASSDEVICE ON CALL — A new imaging tool could help cardiologists better determine which patients are at the highest risk of sudden cardiac arrest and would most likely benefit from receiving an implanted cardioverter defibrillator, according to researchers at the University of Buffalo.
The researchers reported the findings of the UB Parapet study, touted as the largest PET study imaging study ever done on cardiac arrest, at this year’s Heart Rhythm Society meeting.
ACC roundup: The top headlines from today’s meeting of American College of Cardiology
AtriCure aims for FDA approval with “hybrid” atrial fibrillation trial
The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure Inc.’s (NSDQ:ATRC) U.S. business, the company’s CEO said.
The pivotal clinical trial, which could lead to regulatory approval of the hybrid procedure to treat atrial fibrillation and is called DEEP AF, will involve expanding studies from six research centers to 35, CEO David Drachman said.
Philips inks deal with Mass. vascular robots firm
Royal Philips Electronics (NYSE:PHG) is adding a robotic system to its treatment options for clogged heart arteries in a new pact with Natick, Mass.-based Corindus Inc.
Corindus begins robotic-assisted stent trial | Research Roundup
Corindus Vascular Robotics began the clinical trial of its CorPath 200 system for placing coronary stents with a pair of procedures in New York and Boston.
The Natick, Mass.-based company said the first procedures in the 154-patient trial, called the Percutaneous Robotic-Enhanced Coronary Intervention Study, were performed at New York-Presbyterian Hospital/Columbia University Medical Center in New York and St. Elizabeth’s Medical Center in Boston.
Regulatory roundup: St. Jude Medical wins Australian, Malaysian approvals
Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies: